Pictet Asset Management’s Nurix Therapeutics NRIX Stock Holding History

Pictet Asset Management’s Portfolio NRIX Stock Details NRIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$42.3M	Sell	2,726,138 -741,462	-21%	-$12.3M	0.04%	345
2025 Q4	$65.8M	Buy	3,467,600 +1,487,060	+75%	+$21.4M	0.06%	283
2025 Q3	$18.3M	Sell	1,980,540 -18,094	-0.9%	-$188K	0.02%	538
2025 Q2	$22.8M	Buy	1,998,634 +244,354	+14%	+$2.64M	0.02%	481
2025 Q1	$20.8M	Sell	1,754,280 -14,637	-0.8%	-$245K	0.02%	483
2024 Q4	$33.3M	Sell	1,768,917 -19,613	-1%	-$450K	0.04%	378
2024 Q3	$40.2M	Buy	1,788,530 +615,012	+52%	+$13.9M	0.04%	336
2024 Q2	$24.5M	Buy	1,173,518 +446,577	+61%	+$6.95M	0.03%	418
2024 Q1	$10.7M	Sell	726,941 -46,647	-6%	-$502K	0.01%	636
2023 Q4	$7.98M	Sell	773,588 -124,221	-14%	-$851K	0.01%	695
2023 Q3	$7.06M	Buy	+897,809	New	+$8.2M	0.01%	694

Other funds holding NRIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Pictet Asset Management's NRIX Position: Q1 2026 in Review

Pictet Asset Management reduced its Nurix Therapeutics (NRIX) stake by 21% in Q1 2026, selling an estimated $12.3M and leaving 2,726,138 shares worth $42.3M. The position accounts for 0.04% of the portfolio, ranked #345.

Pictet Asset Management first reported a position in NRIX in Q3 2023 and has held it in 11 quarters since. The position peaked at $65.8M in Q4 2025. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

Pictet Asset Management held 2,726,138 shares of Nurix Therapeutics worth $42.3M as of Q1 2026.
Pictet Asset Management sold 741,462 Nurix Therapeutics shares in Q1 2026, an estimated $12.3M.
Nurix Therapeutics made up 0.04% of Pictet Asset Management's portfolio in Q1 2026, its #345 holding.
Pictet Asset Management first reported a position in Nurix Therapeutics in Q3 2023 and has held it in 11 quarters since.
Pictet Asset Management's Nurix Therapeutics position peaked at $65.8M in Q4 2025.
195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Pictet Asset Management's 13F filing for Q1 2026, filed 22 Apr 2026.